1849 bioSummer 2024Active☆Watch⊞Compare

1849 bio is one of 233 Biotech companies tracked from San Francisco, CA, USA, on record since 2024. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Engineering microbes for miners to unlock billions in trapped metal

1849 bio designs microbes enabling cheap metal extraction allowing miners to unlock value from low quality copper and gold ores. Surprisingly, the mining industry is one of the largest scale users of biotech in the world with biomining processes accounting for ~1% of global copper production. Biomining is ultra-low cost, running around ~$1/ton of ore vs ~$7/ton for conventional processes. Unfortunately, while biomining is cheap, it can’t be applied to over 80% of copper ores, leaving vast resources without profitable extraction methods. An estimated ~$800B of copper sit today in waste materials and stockpiles with negative unit economics. While a great deal of effort has been spent on optimizing microbial metal extraction processes, very little effort has been spent on optimizing the microbes themselves. To change that, we’re creating new biotech tools and platforms applied directly to the types of biology most relevant to miners. This enables us to develop new microbes and tackle some of the most difficult problems in biomining, unlocking billions in value from unprofitable resources while being more environmentally friendly than conventional processes. We’re world class microbial engineers. We met while doing our PhDs in synthetic biology, where we spent our time applying and developing the most advanced bioengineering technologies to engineer living cells. 

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

No staged rounds to sequence.

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 67% of sector peers (real $). Modeled value above 67% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

1849 bio is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where 1849 bio sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at 1849 bio, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.